Levosimendan Altan

Levosimendan, the active ingredient in Levosimendan Altan, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It is employed to improve cardiac contractility in patients with acute decompensated heart failure and works by sensitizing troponin C to calcium while opening ATP‑sensitive potassium channels, leading to enhanced contractility and vasodilation.

GNH USA supplies Levosimendan Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, providing reliable global distribution and regulatory support.

Levosimendan is a calcium sensitizer used in the management of heart failure.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of low perfusion. Chronic heart failure (intermittent infusion): may enhance hemodynamic stability and exercise capacity. Cardiogenic shock (off‑label): may support myocardial contractility when conventional therapy is insufficient. Post‑cardiac surgery low‑output syndrome: helps restore adequate cardiac output during early recovery.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Hypotension - Nausea - Dizziness - Tachycardia - Mild arrhythmia

Serious or Rare Side Effects: - Severe hypotension - Ventricular arrhythmias - Myocardial ischemia - Allergic reactions (anaphylaxis) - Elevated liver enzymes

When using Levosimendan, clinicians should observe specific precautions to minimize risk.

Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. Blood pressure monitoring: watch for hypotension, especially in patients on other vasodilators. Electrolyte balance: correct potassium and magnesium abnormalities before administration. Renal function: adjust use in severe renal impairment. Hepatic impairment: use cautiously in patients with liver dysfunction. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase levosimendan exposure. - Concurrent use with other vasodilators (e.g., nitrates, hydralazine): may cause severe hypotension. - Other calcium sensitizers (e.g., pimobendan): additive inotropic effect, risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - Diuretics: may exacerbate electrolyte disturbances. - ACE inhibitors or ARBs: combined effect on blood pressure.